Blood: Physiologic Functions, Hemostasis, Disorders of Coagulation, and Clinical Recognition of Abnormal Bleeding

Blood is a specialized connective tissue that delivers oxygen and nutrients, removes carbon dioxide and metabolic waste, and coordinates immune and hemostatic responses. It consists of plasma (the liquid component) and formed elements: erythrocytes (red blood cells), leukocytes (white blood cells), and platelets. Plasma is rich in water, electrolytes, albumin, globulins, and clotting factors. Erythrocytes contain hemoglobin, which binds oxygen in the lungs and releases it in peripheral tissues; they also contribute to acid–base buffering. Leukocytes provide innate and adaptive immune defense through phagocytosis, cytokine signaling, antigen presentation, and antibody-mediated mechanisms. Platelets support primary hemostasis by adhering to damaged endothelium and aggregating to form a platelet plug. Collectively, these components maintain circulatory stability and protect against infection and hemorrhage.

Hemostasis is the tightly regulated process that prevents blood loss after vascular injury. It is classically divided into primary hemostasis (platelet plug formation) and secondary hemostasis (coagulation cascade leading to fibrin clot stabilization), followed by fibrinolysis (clot removal). After endothelial disruption, subendothelial collagen and tissue factor expose binding sites. von Willebrand factor mediates platelet adhesion via glycoprotein Ib, while platelet activation triggers release of granule contents such as ADP and thromboxane A2, promoting recruitment and aggregation through glycoprotein IIb/IIIa. Secondary hemostasis converts soluble fibrinogen into insoluble fibrin via thrombin generation. This cascade involves intrinsic and extrinsic pathways converging on factor X and producing thrombin, which amplifies clot formation by activating factors V, VIII, and XI and by converting fibrinogen to fibrin. Finally, fibrinolysis dissolves clots through plasmin generated from plasminogen by tissue plasminogen activator, preventing pathological persistence of thrombi.

Abnormal bleeding reflects either impaired coagulation, insufficient platelets, abnormal vessel integrity, or dysregulated fibrinolysis. Thrombocytopenia can result from decreased production (e.g., bone marrow suppression), increased consumption (e.g., immune thrombocytopenia, disseminated intravascular coagulation), or sequestration (e.g., hypersplenism). Congenital or acquired platelet function disorders impair clot stability despite normal platelet counts. Coagulation factor deficiencies include hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency), while von Willebrand disease causes defective platelet adhesion and variable factor VIII reduction. Anticoagulant exposure (heparin, warfarin, direct oral anticoagulants) can also produce clinically significant bleeding.

Clinically, bleeding patterns help localize the problem. Mucocutaneous bleeding such as epistaxis, gingival bleeding, easy bruising, and heavy menstrual bleeding suggests platelet disorders or vWD. Deep tissue bleeding (muscle, joints) and delayed bleeding after trauma are more characteristic of hemophilia. Systemic bleeding with oozing from puncture sites can be seen in consumptive coagulopathies such as DIC, where widespread clotting consumes platelets and coagulation factors. Life-threatening hemorrhage requires rapid recognition: hypotension, tachycardia, altered mental status, and falling hemoglobin indicate significant blood loss. In such cases, stabilization with airway and breathing, IV access, hemostatic resuscitation, and reversal of anticoagulation when appropriate are time-critical.

Diagnostic evaluation typically starts with history (medications, family history, prior bleeding), physical exam, and baseline labs. A complete blood count assesses hemoglobin and platelet number; peripheral smear may suggest hemolysis or marrow disorders. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) screen for pathway defects: prolonged PT suggests extrinsic/common pathway issues; prolonged aPTT suggests intrinsic/common pathway issues; combined prolongation can indicate multiple factor deficiencies or DIC. Specific factor assays, von Willebrand testing (antigen, activity, and multimer analysis), and platelet function studies refine diagnosis. If bleeding is brisk, clinicians may proceed with empiric hemostatic therapy while awaiting confirmatory tests.

Treatment depends on etiology and severity. Platelet transfusion is used for severe thrombocytopenia with active bleeding or before invasive procedures when indicated. Desmopressin (DDAVP) can increase circulating von Willebrand factor and factor VIII in selected patients with mild hemophilia A and many cases of mild vWD. Hemophilia management includes factor replacement (factor VIII or IX concentrates) and, for some patients, extended half-life therapies. Antifibrinolytics such as tranexamic acid can reduce bleeding in mucosal sites. For DIC, therapy targets the underlying trigger (e.g., infection, malignancy, obstetric complications) alongside supportive transfusion and anticoagulation in selected thrombotic-dominant scenarios.

When encountering social media statements that mention blood or bleeding, it is essential to distinguish educational discussion from self-harm intent. If there is any indication of self-injury, immediate support is warranted. In medical contexts, abnormal bleeding should be treated as a potentially serious symptom requiring prompt clinical assessment, especially with heavy bleeding, dizziness, fainting, severe pain, or signs of anemia.

Source: @wristslittr (Original post: blood ahh blood, Jun 10, 2026)